MediciNova (MNOV) to Post Earnings on Thursday

MediciNova (NASDAQ:MNOV) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.0750 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

MediciNova (NASDAQ:MNOV) last posted its quarterly earnings data on Thursday, May 14th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. MediciNova had a negative net margin of 1,962.98% and a negative return on equity of 27.28%. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.19 million. On average, analysts expect MediciNova to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

MediciNova Trading Down 1.5%

MNOV stock opened at $1.32 on Tuesday. The stock has a market cap of $64.97 million, a P/E ratio of -5.74 and a beta of 0.63. The stock’s fifty day simple moving average is $1.34 and its two-hundred day simple moving average is $1.42. MediciNova has a 1-year low of $1.17 and a 1-year high of $1.96.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. StoneX Group Inc. bought a new position in shares of MediciNova in the fourth quarter worth $25,000. Goldman Sachs Group Inc. purchased a new stake in MediciNova during the 4th quarter worth about $35,000. Citadel Advisors LLC bought a new position in MediciNova in the 3rd quarter worth about $92,000. Jane Street Group LLC purchased a new position in MediciNova during the 4th quarter valued at about $214,000. Finally, State Street Corp increased its position in shares of MediciNova by 10.9% during the fourth quarter. State Street Corp now owns 193,698 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 19,100 shares during the period. 9.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on MNOV shares. D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of MediciNova in a report on Monday, May 4th. Weiss Ratings restated a “sell (d-)” rating on shares of MediciNova in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.33.

About MediciNova

MediciNova, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.

The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness.